Cargando…
Antibody–Drug Conjugates for Cancer Therapy
Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344263/ https://www.ncbi.nlm.nih.gov/pubmed/28536381 http://dx.doi.org/10.3390/biomedicines4030014 |
_version_ | 1782513503081332736 |
---|---|
author | Parslow, Adam C. Parakh, Sagun Lee, Fook-Thean Gan, Hui K. Scott, Andrew M. |
author_facet | Parslow, Adam C. Parakh, Sagun Lee, Fook-Thean Gan, Hui K. Scott, Andrew M. |
author_sort | Parslow, Adam C. |
collection | PubMed |
description | Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance. |
format | Online Article Text |
id | pubmed-5344263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53442632017-05-23 Antibody–Drug Conjugates for Cancer Therapy Parslow, Adam C. Parakh, Sagun Lee, Fook-Thean Gan, Hui K. Scott, Andrew M. Biomedicines Review Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance. MDPI 2016-07-11 /pmc/articles/PMC5344263/ /pubmed/28536381 http://dx.doi.org/10.3390/biomedicines4030014 Text en © 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Parslow, Adam C. Parakh, Sagun Lee, Fook-Thean Gan, Hui K. Scott, Andrew M. Antibody–Drug Conjugates for Cancer Therapy |
title | Antibody–Drug Conjugates for Cancer Therapy |
title_full | Antibody–Drug Conjugates for Cancer Therapy |
title_fullStr | Antibody–Drug Conjugates for Cancer Therapy |
title_full_unstemmed | Antibody–Drug Conjugates for Cancer Therapy |
title_short | Antibody–Drug Conjugates for Cancer Therapy |
title_sort | antibody–drug conjugates for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344263/ https://www.ncbi.nlm.nih.gov/pubmed/28536381 http://dx.doi.org/10.3390/biomedicines4030014 |
work_keys_str_mv | AT parslowadamc antibodydrugconjugatesforcancertherapy AT parakhsagun antibodydrugconjugatesforcancertherapy AT leefookthean antibodydrugconjugatesforcancertherapy AT ganhuik antibodydrugconjugatesforcancertherapy AT scottandrewm antibodydrugconjugatesforcancertherapy |